BERYL DRUGS LTD. (BERLDRG) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of BERYL DRUGS LTD. ₹15.48, price ₹25.29, upside -38.8%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch BERYL DRUGS LTD. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹5.52 – ₹44.40 · fair‑value band ₹12.56 – ₹17.00 · the ₹25.29 price screens above the ₹15.48 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow BERYL DRUGS in your weekly email
Every Wednesday you see whether BERYL DRUGS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BERYL DRUGS LTD. (BERLDRG) currently trades at ₹25.29, while our model-based Fair Value estimate is ₹15.48, 38.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹16.75 per share, and 2 of the 12 models we run sit above the ₹25.29 price.
Bear case: the Earnings-Based group reads lowest at ₹10.89, and 10 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹12.56 (bear) to ₹17.00 (bull), the price of ₹25.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
BERYL DRUGS LTD. reported revenue of ₹188M in FY2026 versus ₹145M in FY2022, a compound +6.8%/yr. Reported net income was ₹4.2M in FY2026.
Key figures
Market cap ₹128M (≈ $1.3M) · P/E ratio 20.4 · P/S ratio 0.46 · EPS (TTM) ₹1.24 · Net margin 2.3% · Return on equity 4.4% · Return on assets (EBIT) 5.0% · Operating margin 4.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 50% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at −39%, BERLDRG screens richer than that median.
Fair Value models
Bear ₹12.56Fair Value ₹15.48Bull ₹17.00
Price ₹25.29 · Upside -38.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.6353 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+33.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+33.6%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 5%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)Healthcare · 142 stocks
Beats the sector median on 7/11 measures
Overall it ranks above its sector peers.
Valuation
Quality Score52 · Above median
Fair Value upside−38.8% · Below median
Profitability
Return on equity (TTM)4.4% · Below median
Return on assets3.8% · Above median
Net margin (TTM)2.9% · Below median
Operating margin (TTM)4.6% · Below median
Growth and dividend
Revenue growth52.2% · Top 25%
Valuation Multiplesvs Healthcare median · lower = cheaper
P/E (TTM)20.4× · Cheaper than median
P/B1.30× · Cheaper than median
P/S (TTM)0.60× · Cheaper than median
EV/EBITDA4.7× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)100· sector 26
PAST (return on equity)18· sector 15
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BERYL DRUGS LTD. (BERLDRG) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹15.48 versus a price of ₹25.29, about −39% upside (overvalued).
What is the fair value of BERLDRG?
Our model-based fair value for BERYL DRUGS LTD. is ₹15.48 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹25.29.
What is the quality score of BERLDRG?
BERYL DRUGS LTD. has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BERYL DRUGS LTD. (BERLDRG)?
Our model-based price target is the fair value of ₹15.48 (as of Oct 3, 2026) from 12 valuation models. Cautious scenario ₹12.56, optimistic scenario ₹17.00. It is a calculation from audited fundamentals, not an analyst target.
What is the BERYL DRUGS LTD. stock forecast for 2026?
Our models put fair value at ₹15.48, about −39% upside versus a price of ₹25.29 (overvalued). Cautious scenario ₹12.56, optimistic scenario ₹17.00. The calculation is refreshed regularly with new filings.
What is the revenue of BERYL DRUGS LTD. (BERLDRG)?
BERYL DRUGS LTD. reported trailing-twelve-month revenue of about ₹213M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of BERYL DRUGS LTD. (BERLDRG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BERYL DRUGS LTD. it is ₹15.48 per share (as of Oct 3, 2026), against a price of ₹25.29. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is BERYL DRUGS LTD. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, BERLDRG trades above its calculated fair value: price ₹25.29, fair value ₹15.48, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BERLDRG?
No. The price is what the market pays today (₹25.29); the fair value is what the company's own numbers justify (₹15.48). For BERYL DRUGS LTD. the two are ₹9.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is BERYL DRUGS LTD. worth?
The market values BERYL DRUGS LTD. at about ₹128M (market capitalisation, as of Oct 3, 2026). Per share that is ₹25.29; our models calculate a fair value of ₹15.48 per share.
What do the bullish and bearish scenarios say about BERLDRG?
Our models span a range for BERYL DRUGS LTD.: cautious scenario ₹12.56, base ₹15.48, optimistic ₹17.00 per share (as of Oct 3, 2026, price ₹25.29). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BERLDRG?
BERYL DRUGS LTD. trades at a price-to-earnings ratio of 20.4 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹15.48 is built from several models across several years. Other multiples: P/B 1.3, P/S 0.6, EV/EBITDA 4.7.
How solid is the balance sheet of BERYL DRUGS LTD. (BERLDRG)?
Balance-sheet figures for BERYL DRUGS LTD. (as of Oct 3, 2026): return on equity 4.4%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is BERLDRG from its 52-week high?
BERYL DRUGS LTD. trades at ₹25.29, about 1% below its 52-week high of ₹25.65 and 50% above the low of ₹16.87 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹15.48 is for.
Which stocks are comparable to BERYL DRUGS LTD.?
From the same area (Healthcare) we also value Anuh Pharma Limited, CORALAB, Eli Lilly and Company, Johnson & Johnson,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BERYL DRUGS LTD. stock attractive at the current price?
The data as of Oct 3, 2026: price ₹25.29, calculated fair value ₹15.48 (−39%), Quality Score 52/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BERLDRG calculated?
We run BERYL DRUGS LTD. through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹15.48, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. BERYL DRUGS LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BERYL DRUGS LTD. (BERLDRG)?
The closing price on Oct 1, 2026 was ₹25.29. Our model-based fair value is ₹15.48, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BERYL DRUGS LTD. right now?
The price sits above even our optimistic bull case (₹17.00). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of BERYL DRUGS LTD.
How large is the market capitalisation of BERYL DRUGS LTD. (BERLDRG)?
The market capitalisation of BERYL DRUGS LTD. is ₹128M (≈ $1.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BERYL DRUGS LTD. (BERLDRG)?
The price-to-sales ratio of BERYL DRUGS LTD. is 0.46 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BERYL DRUGS LTD. (BERLDRG)?
Earnings per share at BERYL DRUGS LTD. are ₹1.24 (price ÷ EPS = P/E 20.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BERYL DRUGS LTD. (BERLDRG)?
The net margin of BERYL DRUGS LTD. is 2.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BERYL DRUGS LTD. (BERLDRG)?
The return on equity (ROE) of BERYL DRUGS LTD. is 4.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BERYL DRUGS LTD. (BERLDRG)?
On an EBIT basis the return on assets of BERYL DRUGS LTD. is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BERYL DRUGS LTD. (BERLDRG)?
The operating margin of BERYL DRUGS LTD. is 4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BERYL DRUGS LTD. (BERLDRG)?
Revenue at BERYL DRUGS LTD. is growing +52.2% versus a year earlier (3y avg −11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BERYL DRUGS LTD. (BERLDRG)?
Earnings per share at BERYL DRUGS LTD. are growing +272% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BERYL DRUGS LTD. (BERLDRG) generate?
The free cash flow of BERYL DRUGS LTD. is −₹1.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BERYL DRUGS LTD. (BERLDRG) carry?
The net debt of BERYL DRUGS LTD. is ₹21.2M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BERYL DRUGS LTD. in the live analysis
One click puts BERYL DRUGS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
